ORTIFAV Trademark

Trademark Overview

On Thursday, July 10, 2025, a trademark application was filed for ORTIFAV with the United States Patent and Trademark Office. The USPTO has given the ORTIFAV trademark a serial number of 99276861. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, December 23, 2025. This trademark is owned by Avyxa Pharma LLC. The ORTIFAV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer
ortifav

General Information

Serial Number99276861
Word MarkORTIFAV
Filing DateThursday, July 10, 2025
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, December 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 13, 2026

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 10, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAvyxa Pharma LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Thursday, July 10, 2025NEW APPLICATION ENTERED
Thursday, July 10, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 10, 2025APPLICATION FILING RECEIPT MAILED
Sunday, November 30, 2025ASSIGNED TO EXAMINER
Thursday, December 11, 2025NON-FINAL ACTION WRITTEN
Thursday, December 11, 2025NON-FINAL ACTION E-MAILED
Thursday, December 11, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, December 13, 2025EXAMINERS AMENDMENT -WRITTEN
Saturday, December 13, 2025EXAMINERS AMENDMENT E-MAILED
Saturday, December 13, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, December 13, 2025EXAMINER'S AMENDMENT ENTERED
Saturday, December 13, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 7, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Related Keywords

ortifav cancer treatment preparations pharmaceutical